Targeted Onc

🎉 Introducing Targeted Onc!  New name. New look. Same focus. 💜   Targeted Oncology™ is now Targeted Onc, continuing our mission to connect science to practice and deliver actionable insights for community oncologists.  Explore: hubs.li/Q04CB_950

Adding a personalized mRNA vaccine to pembrolizumab cut the risk of recurrence or death by 42% in resected #melanoma. @DrKarenKnudsen of @parkerici discusses why the benefit emerged only after 6 months, and why overall survival data are still key. 🎥 targetedonc.com/view/phase-3…

🎥 A little behind-the-scenes at #CFS2026: Prakash Peddi, MD (@WKHeath) shares insights on emerging therapies in HR+/HER2− breast cancer. #BreastCancer #Oncology

The #NCCN #prostatecancer guidelines now include the ArteraAI Prostate Test (Post-RP), an AI-based digital pathology tool, for risk stratification in biochemical recurrence after radical prostatectomy. 🔗 targetedonc.com/view/arteraa…

📊 New #CTOS26 data: EFTISARC-NEO reported 94.1% 12-month local recurrence-free survival and 86.2% distant metastasis-free survival in #SoftTissueSarcoma. #CancerNews #Oncology Read more: tinyurl.com/4m3r62u8

We’re on site in NYC for #CFS2026! 🗽🎥 The Targeted Onc team is connecting with leading voices across oncology to bring you the latest insights, conversations, and perspectives shaping the future of cancer care. Stay tuned for coverage from the conference!

🧠 What led to the @FDA 's not approvable decision for Optune Mya? Review the METIS trial findings, including delayed intracranial progression without a significant overall survival benefit, and @Novocure's planned next steps. #NSCLC #BrainMetastases tinyurl.com/b9y3yjw3

New name. Same commitment to community oncology. 💜 From emerging research to expert perspectives, we’ll keep bringing you insights you can use in everyday practice.   Explore the new Targeted Onc at hubs.li/Q04DW5Bz0 #TargetedOnc #CommunityOncology

Kohei Shitara, MD, discusses safety and tolerability findings from G-HOPE-001 evaluating arcotatug tavatecan in previously treated, CLDN18.2-positive advanced #GastricCancer. 🎥 WATCH: targetedonc.com/view/arcotat… #GICancers #Oncology #ESMO26 | @KoheiShitara

🔬 How does JNJ-6143 target advanced #ProstateCancer? @BGarmezy , MD, explains how the investigational RIPTAC therapy brings AR and BRD4 together to disrupt cancer cell survival. #GUOnc #Oncology WATCH: tinyurl.com/3bhn37w4

OncoMate MSI Dx, already cleared for Lynch syndrome testing in colorectal cancer and used to select MSS endometrial cancer for pembrolizumab plus lenvatinib, is now an FDA-approved companion test for pembrolizumab in MSI-H solid tumors. 🔗 targetedonc.com/view/oncomat… #immunotherapy

🔬 Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory #LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy. Read more: targetedonc.com/view/anbalca… #Lymphoma #CARTCellTherapy #Hematology #Oncology

Ponatinib plus blinatumomab improved 24-month EFS vs imatinib plus chemotherapy in newly diagnosed #PhALL (86% vs 67%) in the phase 3 GIMEMA ALL2820 trial. #Leukemia READ: tinyurl.com/4fvhdt88

🔬 A study of more than 205,000 patients with advanced cancer found that physician and practice factors influence #ClinicalTrial enrollment, highlighting opportunities to improve access and address participation disparities. Read more: targetedonc.com/view/physici…

Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. 🎥 WATCH: targetedonc.com/view/dr-shit… #GICancers #Oncology #ESMO26 | @KoheiShitara

🎥 JNJ-6143 has shown antitumor activity in heavily pretreated #ProstateCancer, but can responses be durable in earlier settings? @BGarmezy MD, discusses key questions for the investigational therapy. WATCH: tinyurl.com/3cuwda8v #GUOnc #Oncology

🚨The FDA has approved pimicotinib (Pimjetmi) for adults with symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity. Dosing is 50 mg once daily. targetedonc.com/view/pimicot…

🎦 WATCH: In KRASCENDO-1, divarasib improved median PFS (9.8 vs 5.7 months) and OS (17.7 vs 12 months) vs sotorasib or adagrasib. Bo Wang, MD of @WVcancer explains how 10- to 100-fold greater potency and selectivity drive the benefit. targetedonc.com/view/next-ge…

#FDA feedback on updated phase 2 results will lead to a planned phase 3 trial of silevertinib vs osimertinib or afatinib in non-classical #EGFR-mutant #NSCLC with untreated brain metastases. 🔗 targetedonc.com/view/silever…

🔬 Patients with relapsed or refractory #CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302. Read more: targetedonc.com/view/denileu… #CancerCare #Lymphoma #SkinHealth #Oncology

🏠 Could home-based trastuzumab administration help reduce the burden of cancer care? New research highlights potential time and cost savings for patients and health care professionals. Read more: tinyurl.com/38pmy6jc #BreastCancer #HER2Positive #Oncology